CD200 genotype is associated with clinical outcome of patients with multiple myeloma
dc.contributor.author
dc.date.accessioned
2024-07-09T10:53:55Z
dc.date.available
2024-07-09T10:53:55Z
dc.date.issued
2024-02-22
dc.identifier.uri
dc.description.abstract
Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media
dc.relation.isformatof
Reproducció digital del document publicat a: https://doi.org/10.3389/fimmu.2024.1252445
dc.relation.ispartof
Frontiers in Immunology, 2024, vol. 15, art.núm.1252445
dc.relation.ispartofseries
Articles publicats (D-CM)
dc.rights
Attribution 4.0 International
dc.rights.uri
dc.subject
dc.title
CD200 genotype is associated with clinical outcome of patients with multiple myeloma
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.identifier.idgrec
037302
dc.type.peerreviewed
peer-reviewed
dc.identifier.eissn
1664-3224